What is the effect of dihydropyridine calcium channel blockers (CCBs) and angiotensin receptor blockers (ARBs) on graft loss?
The evidence review found that dihydropyridine CCB use caused a reduction in graft loss of 68% (RR: 0.32; 95% CI: 0.18 0.55) compared to placebo/no treatment. This evidence was derived from 8 RCTs involving 926 participants followed for a mean of 25 months. In contrast, the reduction in graft loss caused by the non-dihydropyridine CCB group was not statistically significant (RR: 0.91; 95% CI: 0.61 1.34) compared to placebo. The evidence review also found that ARB use compared to placebo caused a 65% reduction in graft loss (RR: 0.35; 95% CI: 0.15 0.84).